腺相关病毒载体:通往肿瘤基因治疗的桥梁  

Adeno-associated virus(AAV)-based vector:a bridge towards tumor gene therapy

作　　者：陈秀生[1] 林创珍 雷川[1] 翟向明[1] 聂鑫[1] 胡奥[1] 陈思[1] 杜红延[1] 

机构地区：[1]南方医科大学生物技术学院,广东广州510515 [2]南方医科大学第一临床医学院,广东广州510515

出　　处：《分子诊断与治疗杂志》2015年第3期193-198,共6页Journal of Molecular Diagnostics and Therapy

基　　金：国家高技术研究发展计划(863计划)(2012AA020205);国家自然科学基金(81401920);2013国家教育部博士点基金(20134433120020);2013年国家级"大学生创新创业训练计划"项目(1212113058);南方医科大学基础研究前期启动项目(QD2013N005);广东省"大学生创新训练计划"(201412121094)

摘　　要：腺相关病毒(adeno-associated virus,AAV)是一种有缺陷的非致病的人类细小病毒。腺相关病毒载体作为基因治疗的载体,对长期基因矫正和基因治疗具有一定优越性。由于其低致病性、易操作性等优点,腺相关病毒载体被作为转导目的基因的理想载体,现已广泛地应用于多种肿瘤等疾病的基因治疗研究中。通过对腺相关病毒载体的改造优化,增加其靶向性,减少免疫原性,有望为相关疾病的基因治疗研究提供新的手段和方法。本文就目前腺相关病毒在肿瘤治疗中的应用研究加以综述,旨在对病毒载体在肿瘤生物治疗领域中的应用提供相应的参考。Adeno-associated virus（AAV）is a kind of human parvovirus that is defective and non-pathogenic. AAV vector, as the vector of gene-therapy, has superiority in long-term gene-correction and gene-therapy. AAV vector is considered to be the ideal vector to transfect target gene because of its mildly pathogenicity and easy to operation and now it has been widely used in different kinds of research on gene-therapy to neoplastic disease. Through improving its targeting and reducing its immunogenicity by reforming and optimizing the AAV vector, it is hopeful to provide new methods and measures to the research about gene-therapy of tumor. In this paper many researches on application of AAV vector in tumor gene therapy are summarized, which will be helpful for studies on tumor gene therapy.

关 键 词：腺相关病毒 基因治疗 应用 研究进展 

分 类 号：R730.5[医药卫生—肿瘤]